SLC18A3: A Potential Drug Target and Biomarker for Cancer (G6572)

Target Name: SLC18A3

NCBI ID: G6572

SLC18A3

SLC18A3: A Potential Drug Target and Biomarker for Cancer

SLC18A3 (CMS21) is a protein that is expressed in various tissues throughout the body. It is a member of the SLC family of transport proteins, which are known for their ability to transport a wide variety of molecules across cell membranes. One of the unique features of SLC18A3 is its ability to interact with the drug drug target (DDR) protein, which is a protein that is targeted by drugs in the treatment of various diseases, including cancer.

SLC18A3 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that high levels of SLC18A3 can promote the growth and survival of cancer cells, while low levels have been associated with the inhibition of cell growth and the inhibition of the development of cancer.

In addition to its role in the regulation of cellular processes, SLC18A3 has also been shown to be a potential drug target (or biomarker) for the treatment of various diseases. For example, studies have shown that inhibiting the activity of SLC18A3 has been shown to be effective in the treatment of cancer, including breast cancer, lung cancer, and ovarian cancer.

The potential benefits of targeting SLC18A3 with drugs are significant. By inhibiting the activity of this protein, researchers hope to reduce the growth and survival of cancer cells and, in turn, to slow the progression of cancer. This could lead to a more effective treatment of cancer and a reduced risk of relapse.

In addition to its potential as a drug target, SLC18A3 is also being studied as a potential biomarker for the diagnosis and monitoring of cancer. Studies have shown that the levels of SLC18A3 in cancer cells can be significantly increased compared to the levels in normal cells, which makes it a promising marker for the detection and diagnosis of cancer.

Furthermore, SLC18A3 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of other diseases, including neurodegenerative disorders and autoimmune diseases.

In conclusion, SLC18A3 is a protein that has the potential to be a drug target (or biomarker) for the treatment of various diseases, including cancer. Its ability to interact with the drug drug target (DDR) protein makes it an attractive target for researchers to study and develop new treatments. Further studies are needed to fully understand the role of SLC18A3 in the regulation of cellular processes and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 18 Member A3

Functions: Electrogenic antiporter that exchanges one cholinergic neurotransmitter, acetylcholine or choline, with two intravesicular protons across the membrane of synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to store neurotransmitters inside the vesicles prior to their release via exocytosis (PubMed:8910293, PubMed:20225888) (By similarity). Determines cholinergic vesicular quantal size at presynaptic nerve terminals in developing neuro-muscular junctions with an impact on motor neuron differentiation and innervation pattern (By similarity). Part of forebrain cholinergic system, regulates hippocampal synapse transmissions that underlie spatial memory formation (By similarity). Can transport serotonin

The "SLC18A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC18A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets